glp 1 hong kong Weixiumei Wegovy® Semaglutide Weight Loss Injections | Prescribed by Doctors Wegovy (Semaglutide) GLP-1｜Begin Your Scientific

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications

GLP-1 drugs like Ozempic and Zepbound have gained significant attention for treating both diabetes and assisting with weight loss.

Experts explain why hunger, food noise and other health changes return after stopping weight loss drugs and how to hold onto your progress.

Records were reviewed for patient characteristics and medication type and doses

Richmond Hill, NY